Navigation Links
MGC Diagnostics Corporation Announces Special Cash Dividend and Extension of Stock Repurchase Program
Date:3/28/2013

SAINT PAUL, Minn., March 28, 2013 /PRNewswire/ -- MGC Diagnostics Corporation (NASDAQ: MGCD), a global medical technology leader, announced that its Board of Directors has approved a special, one-time cash dividend of $0.45 per share on its outstanding common stock, payable on April 26, 2013 to shareholders of record as of April 12, 2013.  The Company also announced an extension of its current Stock Repurchase Program to October 31, 2013.  The Stock Repurchase Program would otherwise expire on July 31, 2013.  This program currently has $2.735 million remaining.

(Logo: http://photos.prnewswire.com/prnh/20120821/LA60189LOGO)

Mark W. Sheffert , Chairman of the Board of Directors of MGC Diagnostics Corporation, stated "The Board of MGC Diagnostics has assessed and will continue to periodically assess the Company's capital resources.  If the Board of Directors determines that the Company's capital resources exceed the amount necessary to meet its working capital and liquidity needs, as well as to retain a reasonable cushion for contingencies and strategic opportunities, then the Company will consider various options for increasing shareholder value, including, but not limited to, purchasing its own shares in the open market and in privately negotiated transactions and paying cash dividends."

"In making the current determination, the MGC Diagnostics Board carefully considered the Company's short- and long-term operating and capital resource needs.  While we expect the Company will continue to pursue opportunistic product line or business acquisitions, given (i) our cash and cash equivalents position of $8.9 million and our positive net working capital position of approximately $13.2 million, both as of January 31, 2013 and (ii) the Board's confidence in management's strategic plan for growth and profitability, the Board determined that it would be able to pay a special one-time cash dividend of $0.45 per share or approximately $1.8 million and still retain adequate funds to meet our working capital and liquidity needs and to pursue strategic opportunities."

Mr. Sheffert concluded, "This is a special one-time cash dividend and MGC Diagnostics cannot guarantee and makes no prediction about future dividends.  Any future dividends will be dependent on the Company's future profitability, cash flow and short- and long-term capital needs." 

About MGC DiagnosticsMGC Diagnostics Corporation, (formerly Angeion Corporation) through its subsidiary Medical Graphics Corporation, is a global medical technology company dedicated to cardiorespiratory health solutions. MGC Diagnostics develops, manufactures and markets non-invasive diagnostic systems. This portfolio of products provides solutions for disease detection, integrated care, and wellness across the spectrum of cardiorespiratory healthcare. The Company's products are sold internationally through distributors and in the United States through a direct sales force targeting heart and lung specialists located in hospitals, university-based medical centers, medical clinics, physicians' offices, pharmaceutical companies, medical device manufacturers, and clinical research organizations (CROs). For more information about MGC Diagnostics, visit www.mgcdiagnostics.com.

Cautionary Statement Regarding Forward Looking StatementsFrom time to time, in reports filed with the Securities and Exchange Commission, in press releases, and in other communications to shareholders or the investing public, MGC Diagnostics Corporation may make forward-looking statements concerning possible or anticipated future financial performance, business activities or plans that include the words "believes," "expects," "anticipates," "intends" or similar expressions. For these forward-looking statements, the Company claims the protection of the safe harbor for forward-looking statements contained in federal securities laws. These forward-looking statements are subject to a number of factors, risks and uncertainties, including those disclosed in our periodic filings with the SEC, that could cause actual performance, activities or plans after the date the statements are made to differ significantly from those indicated in the forward-looking statements. For a list of these factors, see the sections entitled "Risk Factors" and "Cautionary Note Regarding Forward Looking Statements," in the Company's Form 10-K for the year ended October 31, 2012, and any updates in subsequent filings on Form 10-Q or Form 8-K under the Securities Exchange Act of 1934.Contact:

Gregg O. Lehman, Ph.D.

Joe Dorame, Robert Blum, Joe DiazMGC Diagnostics Corporation

Lytham Partners, LLCChief Executive Officer

(602) 889-9700(651) 484-4874

mgcd@lythampartners.com


'/>"/>
SOURCE MGC Diagnostics Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Dominion Diagnostics to Sponsor 2013 Addiction Professional Panel Series as Thought Leadership Partner
2. PrimeraDx to Co-Develop Companion Diagnostics with Quest Diagnostics
3. Boston Heart Diagnostics Awarded $450,000 in Tax Incentives from the Massachusetts Life Sciences Center
4. DMG is Proud to Announce that CD Diagnostics will be Featured in an Upcoming Episode of Health Heroes
5. Personal Genome Diagnostics Inc. Licenses Genome-Mapping Technology from Johns Hopkins University and Expands Its Cancer Genome Analysis Business
6. Advanced Cell Diagnostics Initiates Agreement to Study Biomarkers for Cancer Immunotherapy
7. QualityStar Presenting at Biomarkers & Diagnostics World Congress
8. Ariosa Diagnostics Welcomes New Board Member Michael A. Aicher
9. QIAGEN Unveils Sample-to-Result Next-Generation Sequencing Workflow Designed for Clinical Research and Diagnostics
10. BIT C2 Diagnostics Adds Hematology Competence Center
11. Advanced Cell Diagnostics Appoints Evangeline Gonzalez as Chief Commercial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... , ... June 27, 2016 , ... ... bring innovative medical technologies, services and solutions to the healthcare market. The company's ... of various distribution, manufacturing, sales and marketing strategies that are necessary to help ...
(Date:6/27/2016)... 2016  Liquid Biotech USA ... a Sponsored Research Agreement with The University of ... from cancer patients.  The funding will be used ... with clinical outcomes in cancer patients undergoing a ... be employed to support the design of a ...
(Date:6/24/2016)... on a range of subjects including policies, debt and investment ... Speaking at a lecture to the Canadian Economics ... the country,s inflation target, which is set by both the ... "In certain areas there needs to be frequent ... not sit down and address strategy together?" He ...
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial ... Cary 5000 and the 6000i models are higher end machines that use the more ... the spectrophotometer’s light beam from the bottom of the cuvette holder. , FireflySci ...
Breaking Biology Technology:
(Date:5/12/2016)... 2016 WearablesResearch.com , a brand of ... results from the Q1 wave of its quarterly wearables ... consumers, receptivity to a program where they would receive ... insurance company. "We were surprised to see ... Michael LaColla , CEO of Troubadour Research, "primarily because ...
(Date:4/28/2016)... , April 28, 2016 Infosys ... (NYSE: INFY ), and Samsung SDS, a global ... that will provide end customers with a more secure, fast ...      (Logo: http://photos.prnewswire.com/prnh/20130122/589162 ) , ... but it also plays a fundamental part in enabling and ...
(Date:4/26/2016)... -- Research and Markets has announced the ...  report to their offering.  , ,     (Logo: ... forecast the global multimodal biometrics market to grow ... 2016-2020.  Multimodal biometrics is being implemented ... healthcare, BFSI, transportation, automotive, and government for controlling ...
Breaking Biology News(10 mins):